FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Baruch D. Kuppermann, MD, PhD, delivers an update on Stargardt disease therapies currently in development.
Six companies are testing therapies across multiple stages, Kuppermann told Healio. Two of these therapies are designed to be delivered orally, three are gene therapies, and one is an optogenetic therapy.
“The concept there is that they are interacting with the ABCA4 gene, which is responsible for 95% of the Stargardt disease mutations,” Kuppermann said. “These would be